Search company, investor...

wantai biological

ystwt.cn

About wantai biological

Headquarters Location

Missing: wantai biological's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: wantai biological's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest wantai biological News

Wantai, Other Chinese Firms Whose Covid Jabs Were OKed This Week Sink as Competition Stiffens

Dec 6, 2022

(Yicai Global) Dec. 6 -- Shares in Beijing Wantai Biological Pharmacy Enterprise, Clover Biopharmaceutical and Sinocelltech Group plunged today, despite the three Chinese vaccine makers all securing regulatory approvals for their Covid-19 jabs within the last two days. This could have to do with investor concerns that too many vaccines are coming on the market. Wantai Biological’s share price [SHA:603392] plummeted 8.2 percent to close at CNY137.45 (USD19.7), Clover Biopharma’s stock [HKG:2197] sank 10.1 percent to HKD4.08 (USD0.53) while Sinocelltech [SHA:688520] slumped 8.4 percent to CNY68.15 (USD9.75). Wantai Biological’s Covid-19 nasal spray vaccine, co-developed with Xiamen University and the University of Hong Kong, has been approved for emergency use in China, the Beijing-based company said yesterday. Sinocelltech and Clover Biopharma’s Covid-19 jabs were greenlit by Chinese regulators on Dec. 4. And a fourth vaccine by unlisted WestVac Biopharma was also given the nod yesterday. There are now more than 10 Covid-19 jabs on the market in China, and over 50 worldwide, which means competition is getting more fierce, Beijing-based Sinocelltech said on Dec. 4. More needs to be done to vaccinate the elderly, the country’s cabinet said on Nov. 29. Over 90 percent of those aged 60 and above have received their first Covid-19 jab, but many, especially those aged over 80, have yet to be given booster shots. Editor: Kim Taylor

wantai biological Frequently Asked Questions (FAQ)

    Discover the right solution for your team

    The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

    Request a demo

    CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.